AR116632A1 - Polipéptidos análogos de la amilina humana y sus métodos de uso - Google Patents

Polipéptidos análogos de la amilina humana y sus métodos de uso

Info

Publication number
AR116632A1
AR116632A1 ARP190102894A ARP190102894A AR116632A1 AR 116632 A1 AR116632 A1 AR 116632A1 AR P190102894 A ARP190102894 A AR P190102894A AR P190102894 A ARP190102894 A AR P190102894A AR 116632 A1 AR116632 A1 AR 116632A1
Authority
AR
Argentina
Prior art keywords
methods
analog polypeptides
amylin
disclosed
human
Prior art date
Application number
ARP190102894A
Other languages
English (en)
Spanish (es)
Inventor
James M Way
Ved P Srivastava
William Blackwell
Original Assignee
Intarcia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intarcia Therapeutics Inc filed Critical Intarcia Therapeutics Inc
Publication of AR116632A1 publication Critical patent/AR116632A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
ARP190102894A 2018-10-11 2019-10-10 Polipéptidos análogos de la amilina humana y sus métodos de uso AR116632A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862744236P 2018-10-11 2018-10-11

Publications (1)

Publication Number Publication Date
AR116632A1 true AR116632A1 (es) 2021-05-26

Family

ID=68393080

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102894A AR116632A1 (es) 2018-10-11 2019-10-10 Polipéptidos análogos de la amilina humana y sus métodos de uso

Country Status (14)

Country Link
US (1) US20200115430A1 (fr)
EP (1) EP3864031A1 (fr)
JP (1) JP2022504596A (fr)
KR (1) KR20210091705A (fr)
CN (1) CN113195524A (fr)
AR (1) AR116632A1 (fr)
AU (1) AU2019357621A1 (fr)
BR (1) BR112021006823A2 (fr)
CA (1) CA3116023A1 (fr)
IL (1) IL282079A (fr)
MX (1) MX2021004185A (fr)
SG (1) SG11202103586UA (fr)
TW (1) TW202028228A (fr)
WO (1) WO2020077129A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230040943A (ko) * 2020-04-20 2023-03-23 아이투오 테라퓨틱스, 인코포레이티드 1형 당뇨병에 대한 우수한 혈당 제어를 제공하기 위한 인간 아밀린 유사체 폴리펩타이드의 용도
SI4021929T1 (sl) * 2020-09-24 2023-09-29 Gubra Aps Analogi HAM15-52 z izboljšano močjo receptorja za amilin(HAMY3R)
CN113880935B (zh) * 2021-10-25 2022-08-26 浙江肽昇生物医药有限公司 一种索马鲁肽全保护肽树脂的制备方法、一种索马鲁肽制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
RO117259B1 (ro) 1993-08-09 2001-12-28 Biomeasure Inc. Derivaţi peptidici, terapeutici
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
PT1238660E (pt) 1996-02-02 2005-10-31 Alza Corp Distribuicao sustentada de um agente activo utilizando um sistema implantavel
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
CN100388916C (zh) 1997-12-22 2008-05-21 阿尔扎有限公司 用于控释药物传递装置的速率控制膜
AU1828599A (en) 1997-12-29 1999-07-19 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
CA2316886C (fr) 1997-12-30 2007-09-25 Alza Corporation Systeme d'administration d'agent benefique a obturateur membranaire
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
CN1495198A (zh) 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
JP4383674B2 (ja) 1998-12-31 2009-12-16 インターシア セラピューティクス，インコーポレイティド 空間効率のよいピストンを有する浸透圧送達システム
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE60006100T2 (de) 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
DE60023361T2 (de) 1999-12-21 2006-04-27 Alza Corp., Mountain View Ventil für osmotische vorrichtungen
ES2307619T3 (es) 2000-05-19 2008-12-01 Amylin Pharmaceuticals, Inc. Tratamiento del sindrome coronario agudo con glp-1.
CZ304002B6 (cs) 2000-06-16 2013-08-14 Eli Lilly And Company Analogy peptidu-1 podobného glukagonu
EP1351984A2 (fr) 2000-12-13 2003-10-15 Eli Lilly And Company Glp-1 amide
US7144863B2 (en) 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
JP4227894B2 (ja) 2001-08-23 2009-02-18 イーライ リリー アンド カンパニー グルカゴン様ペプチド１アナログ
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
EP1551493B1 (fr) 2002-06-26 2007-10-31 Alza Corporation Piston peu flexible efficace d'un point de vue volumique pour systemes d'administration de medicaments osmotiques
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
MXPA05010605A (es) 2003-03-31 2005-11-23 Alza Corp Bomba osmotica con medios para disipar la presion interna.
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
EP2422807A3 (fr) 2004-02-11 2012-05-30 Amylin Pharmaceuticals Inc. Polypeptides hybrides présentant des propriétés pouvant être choisies
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
EP1996617A2 (fr) * 2006-03-15 2008-12-03 Novo Nordisk A/S Dérivés d'amyline
DK2020990T3 (da) 2006-05-30 2010-12-13 Intarcia Therapeutics Inc Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem
EP2049081B1 (fr) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Systemes d'administration osmotiques et ensembles pistons
WO2009102467A2 (fr) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Dispositifs, formulations et méthodes d’administration de plusieurs agents bénéfiques
ES2662501T3 (es) * 2008-10-21 2018-04-06 Novo Nordisk A/S Derivados de amilina
US20140221282A1 (en) * 2011-05-25 2014-08-07 Astrazeneca Pharmaceuticals Lp Long duration dual hormone conjugates

Also Published As

Publication number Publication date
BR112021006823A2 (pt) 2021-07-27
WO2020077129A1 (fr) 2020-04-16
JP2022504596A (ja) 2022-01-13
MX2021004185A (es) 2021-09-08
AU2019357621A1 (en) 2021-05-27
IL282079A (en) 2021-05-31
TW202028228A (zh) 2020-08-01
CN113195524A (zh) 2021-07-30
US20200115430A1 (en) 2020-04-16
SG11202103586UA (en) 2021-05-28
KR20210091705A (ko) 2021-07-22
EP3864031A1 (fr) 2021-08-18
CA3116023A1 (fr) 2020-04-16

Similar Documents

Publication Publication Date Title
AR116632A1 (es) Polipéptidos análogos de la amilina humana y sus métodos de uso
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2022010241A2 (es) Inhibidores de sos1
IL310939A (en) Large-scale production of therapeutic preparations enriched in mRNA encoding therapeutic peptides
PE20181139A1 (es) Composiciones y metodos para inhibir la expresion genica de lpa
ECSP14030742A (es) Proteínas del factor 21 de crecimiento del fibroblasto
CR8118A (es) Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
BR112018073511A2 (pt) polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
EA201792602A1 (ru) Стволовые клетки плацентарного происхождения и их применение для восстановления регенеративного механизма, коррекции протеомных дефектов и продления жизни стареющих индивидуумов
CO6280409A2 (es) Anticuerpos antimesotelina y usos de los mismos
AR102301A1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
ECSP22007726A (es) Análogos de relaxina y métodos para usarlos
UY32060A (es) Anticuerpos anti-il-13 obtenidos mediante ingeniería, composiciones , métodos y usos
CO6541604A2 (es) Composiciones orales que contienen extractos de myristica fragrans y métodos relacionados
CU20120116A7 (es) Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5
BR112022019020A2 (pt) Proteínas de fusão de il12 mascaradas e métodos de uso das mesmas
UY38701A (es) Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
UY38200A (es) Conjugados de tirosina-tirosina de péptido cíclico acoplado a péptido de fusión de glp-1 y sus usos
CO2023013465A2 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
CL2020000019A1 (es) Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso.
CL2020002641A1 (es) Composición para modular genes responsables de las funciones generales de la piel, que comprende un extracto vegetal de cichorium intybus y ceramidas de pasionaria (divisional de la solicitud 03354-2018)
BR112021017853A2 (pt) Vetores de dna não virais e usos dos mesmos para expressar terapêuticas de fviii
BR112017006450A2 (pt) vetor adenoviral codificando atonal homólogo-1 de humano (hath1)
AR124395A1 (es) Agonistas del receptor del polipéptido tipo glucagón 1 (glp-1) de acción prolongada y métodos de uso de los mismos